Related Experiment Video

Updated: Aug 8, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Glucuronides in anti-cancer therapy

Xi Chen1, Bingyuan Wu, Peng George Wang

  • 1Department of Chemistry, Wayne State University, Detroit, MI 48202, USA.

Current Medicinal Chemistry. Anti-Cancer Agents
|April 8, 2003
PubMed

Insights

Glucuronide prodrugs offer targeted anti-cancer therapy with reduced toxicity. By leveraging tumor-specific enzymes like beta-glucuronidase, these prodrugs activate into potent agents directly at the tumor site.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Glucuronide prodrugs demonstrate potential in cancer treatment by enhancing specificity and minimizing systemic toxicity.
  • Prodrug monotherapy (PMT) relies on increased beta-glucuronidase activity within tumors to activate prodrugs into cytotoxic agents.
  • This targeted activation ensures that highly toxic compounds are released specifically at the tumor site.

Purpose of the Study:

  • To explore the multifaceted applications of glucuronide prodrugs in anti-cancer strategies.
  • To highlight methods for improving prodrug specificity and potency in cancer therapy.
  • To discuss the integration of prodrugs into advanced therapeutic approaches.

Main Methods:

  • Investigating prodrug monotherapy (PMT) utilizing tumor-specific beta-glucuronidase activity.
  • Examining antibody-directed enzyme prodrug therapy (ADEPT) by combining prodrugs with monoclonal antibodies targeting tumor antigens.
  • Evaluating combined chemo- and radio-therapy of cancer (CCRT) strategies incorporating radionuclides into prodrugs.
  • Assessing the use of prodrugs in liposome-mediated drug delivery systems.

Main Results:

  • Glucuronide prodrugs show promise for targeted cancer therapy, reducing systemic side effects.
  • PMT effectively utilizes elevated tumor beta-glucuronidase for localized prodrug activation.
  • ADEPT enhances specificity through antibody targeting of tumor antigens.
  • Incorporation of radionuclides in CCRTC strategies significantly boosts prodrug potency.
  • Liposome modification with prodrugs facilitates efficient anti-cancer drug delivery.

Conclusions:

  • Glucuronide prodrugs represent a versatile platform for advanced cancer treatment modalities.
  • Strategies like PMT, ADEPT, and CCRTC offer improved specificity and efficacy.
  • Further development of prodrug-based therapies holds significant potential for improving patient outcomes in oncology.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...